Recap: Blueprint Medicines Q2 Earnings

Shares of Blueprint Medicines BPMC remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share fell 11.76% over the past year to ($2.28), which missed the estimate of ($2.14).

Revenue of $8,343,000 up by 63.27% year over year, which beat the estimate of $6,600,000.

Outlook

Blueprint Medicines hasn't issued any earnings guidance for the time being.

Blueprint Medicines hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Jul 30, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/m82wn2p5

Recent Stock Performance

Company's 52-week high was at $101.76

52-week low: $43.29

Price action over last quarter: Up 22.55%

Company Overview

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.